Recursion Pharmaceuticals (RXRX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting much higher quarterly revenue, a smaller net loss, and fresh commentary on its ...

RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA talks.

SAN FRANCISCO -- One new startup is called Recursive with an "e." Another is called Ricursive with an "i." They are trying to do the same thing: Build artificial intelligence that can improve itself ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

We recently published 12 Best Healthcare Stocks to Buy Under $30. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a ...

but it cannot work, so how to query items with all theire children? untill the leaf node? Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment ...

Office Hours: All office hours will be held remotely via Zoom. You may need to wait in the Waiting Room in the case that I am helping someone else. My office hours are TBD. This course covers the ...

Hello there! 👋 I'm Luca, a BI Developer with a passion for all things data, Proficient in Python, SQL and Power BI ...